See What HealthDay Can Do For You
Contact Us

MicroRNAs Distinguish Tumors in Von Hippel-Lindau Syndrome

miR-9, miR-200a differentiate hemangioblastomas from metastatic clear cell renal cell carcinomas

THURSDAY, Dec. 1 (HealthDay News) -- MicroRNA (miRNA), miR-9 and miR-200a, signatures facilitate distinction of hemangioblastomas from metastatic clear cell renal cell carcinomas (Met CCRCC) in Von Hippel-Lindau Syndrome, according to a study published online Nov. 15 in Brain Pathology.

Sriram Venneti, M.D., Ph.D., from the Children's Hospital of Philadelphia, and colleagues investigated whether hemangioblastomas and Met CCRCC can be distinguished histologically by their miRNA signatures. A total of 10 cases each of hemangioblastomas, Met CCRCC, and primary CCRCC were profiled for miRNAs. Confirmation was carried out using quantitative real time reverse transcriptase-polymerase chain reaction (qRT-PCR) on 20 hemangioblastomas, 13 Met CCRCC, and 15 control non-lesional brain tissues, and using in situ hybridization in 15 cases of hemangioblastomas and 10 cases of Met CCRCC.

The investigators found that, compared with Met CCRCC, hemangioblastomas had 10 miRNAs with greater abundance, including miR-9 and miR-135a, and 39 miRNAs with lower abundance, including miR-200a and miR-200b. In qRT-PCR in hemangioblastomas, there was a 12-fold increase in miR-9 and a 15-fold decrease of miR-200a compared to Met CCRCC. These results were confirmed using in situ hybridization.

"Our data suggest that miR-9 and miR-200a can distinguish between hemangioblastomas and Met CCRCC," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.